StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Madrigal Pharmaceuticals's total assets was $1.24B at Jun 30, 2026. For fiscal 2025 it was $1.26B, up 20.9% from the year before. Over ten years it grew 125.9% a year on average. The highest annual figure on record is $1.26B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.26B+20.9%
FY2024Dec 31, 2024$1.04B+62.7%
FY2023Dec 31, 2023$640.55M+76.7%
FY2022Dec 31, 2022$362.57M+32.6%
FY2021Dec 31, 2021$273.33M-4.8%
FY2020Dec 31, 2020$287.00M-35.1%
FY2019Dec 31, 2019$442.06M-8.9%
FY2018Dec 31, 2018$485.43M+152.4%
FY2017Dec 31, 2017$192.31M+366.7%
FY2016Dec 31, 2016$41.21M+11234.5%
FY2015Dec 31, 2015$363.58K-99.6%
FY2014Dec 31, 2014$100.68M+5.7%
FY2013Dec 31, 2013$95.20M-7.6%
FY2012Dec 31, 2012$103.02M+143.4%
FY2011Dec 31, 2011$42.32M-21.7%
FY2010Dec 31, 2010$54.07M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.24B+22.6%
Q1 FY2026Mar 31, 2026$1.23B+23.1%
Q4 FY2025Dec 31, 2025$1.26B+20.9%
Q3 FY2025Sep 30, 2025$1.36B+26.9%
Q2 FY2025Jun 30, 2025$1.02B-7.7%
Q1 FY2025Mar 31, 2025$996.63M-7.9%
Q4 FY2024Dec 31, 2024$1.04B+62.7%
Q3 FY2024Sep 30, 2024$1.07B+351.0%
Q2 FY2024Jun 30, 2024$1.10B+263.6%
Q1 FY2024Mar 31, 2024$1.08B+225.5%
Q4 FY2023Dec 31, 2023$640.55M+76.7%
Q3 FY2023Sep 30, 2023$237.96M+50.0%
Q2 FY2023Jun 30, 2023$302.46M+39.8%
Q1 FY2023Mar 31, 2023$332.45M+49.3%
Q4 FY2022Dec 31, 2022$362.57M+32.6%
Q3 FY2022Sep 30, 2022$158.64M-47.9%
Q2 FY2022Jun 30, 2022$216.39M-34.0%
Q1 FY2022Mar 31, 2022$222.66M-28.1%
Q4 FY2021Dec 31, 2021$273.33M-4.8%
Q3 FY2021Sep 30, 2021$304.70M-10.3%
Q2 FY2021Jun 30, 2021$327.96M-15.6%
Q1 FY2021Mar 31, 2021$309.73M-24.7%
Q4 FY2020Dec 31, 2020$287.00M-35.1%
Q3 FY2020Sep 30, 2020$339.62M-25.6%
Q2 FY2020Jun 30, 2020$388.39M-17.3%
Q1 FY2020Mar 31, 2020$411.46M-14.2%
Q4 FY2019Dec 31, 2019$442.06M-8.9%
Q3 FY2019Sep 30, 2019$456.25M-6.8%
Q2 FY2019Jun 30, 2019$469.82M-4.4%
Q1 FY2019Mar 31, 2019$479.56M+161.4%
Q4 FY2018Dec 31, 2018$485.43M+152.4%
Q3 FY2018Sep 30, 2018$489.55M+679.2%
Q2 FY2018Jun 30, 2018$491.53M+622.1%
Q1 FY2018Mar 31, 2018$183.48M+354.6%
Q4 FY2017Dec 31, 2017$192.31M+366.7%
Q3 FY2017Sep 30, 2017$62.83M+51.4%
Q2 FY2017Jun 30, 2017$68.07M–
Q1 FY2017Mar 31, 2017$40.36M–
Q4 FY2016Dec 31, 2016$41.21M–
Q3 FY2016Sep 30, 2016$41.51M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?